Abstract |
The novel benzodiazepine derivative, meclonazepam (3-methylclonazepam) has been found to be orally effective at high doses against all stages of schistosomiasis. Animals studies have shown it to have a high therapeutic index and a profile of behavioural activity typical of the benzodiazepines. The effects of single oral doses of meclonazepam, 1, 2 and 4 mg on central arousal, psychomotor performance and subjective mood were studied in two double-blind placebo controlled studies in healthy volunteers. In doses exceeding 1 mg, meclonazepam caused marked dose-related impairment in cognitive and psychomotor functions as well as shifts in mood reflecting sedation and ataxia. These effects were most prominent in the first 3 h after administration, with moderate sedation still present 6 h after the 4 mg dose. The implications of these findings for the use of benzodiazepine agents in the treatment of schistosomiasis are discussed.
|
Authors | C O'Boyle, R Lambe, A Darragh |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 29
Issue 1
Pg. 105-8
( 1985)
ISSN: 0031-6970 [Print] Germany |
PMID | 4054198
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Benzodiazepinones
- Schistosomicides
- meclonazepam
|
Topics |
- Adult
- Benzodiazepinones
(pharmacology)
- Brain
(drug effects)
- Humans
- Male
- Psychomotor Performance
(drug effects)
- Schistosomicides
(pharmacology)
|